NCT07048054招募中1 期
Allogenic Adipose-derived Stromal Cell Patch (i.e TrophiPatch, Provided by HekeTiss®) for Chronic Leg Ulcers Resistant to Standard Treatment: Safety and Preliminary Efficacy, a One-arm Monocentric Phase I-ll Trial
Nicolò Brembilla1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2025年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Composite safety outcome at week 12 from baseline
研究概览
简要总结
This study aims to evaluate the safety and effectiveness of an experimental biological dressing called TrophiPatch, applied to adults with chronic leg ulcers of diabetic or vascular orign. TrophiPatch contains stromal cells derived from a donor's fat tissue, which are purified and processed in a certified laboratory. These cells have shown wound-healing, anti-inflammatory and pro-angiogenic properties in preclinical studies.
All 18 participants will receive a single application of TrophiPatch on their wound. The total study duration is up to 24 weeks, with 23 scheduled visits for follow-up and monitoring.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older.
- •Patients with more than one eligible ulcer will have one - usually the largest or more clinically significant - selected at screening as the index ulcer.
- •Participants will have the capacity to understand study procedures, and will be able to providewritten informed consent.
- •(for VLU only)
- •Diagnosed with at least one venous leg ulcer.
- •Ulcers duration for 6 weeks to 3 years at the time of screening.
- •Hard-to-healed ulcers with cross-sectional area that have decreased by less than 40% during a four-week run-in period.
- •Reference ulcer surface from 5 to 25 cm
- •At the time of inclusion, the ulcer will be clinically non-infected (TILI score ≥ 5).
- •Absence of significant arterial insufficiency assessed at clinical examination (intermittent claudication or resting pain, necrotic or distal wound on the foot) and systolic homolateral ankle-brachial index (ABI) greater than 0.75 and inferior to 1.40 or biphasic or triphasic Doppler signals in the dorsalis or posterior tibial arteries of the affected limb.
- •(for DFU only)
- •Patient with type 1 or type 2 diabetes.
- •Diagnosed with at least one diabetic foot ulcer on a foot or both feet below the level of the malleoli, excluding ulcers confined to the interdigital cleft.
- •Ulcers duration for 4 weeks to 3 years at the time of screening.
- •Eligible ulcers will be hard-to-heal, meaning that the cross-sectional area will decrease by less than 50% during a four-week run-in period.
- •Reference ulcer surface from 1 to 25 cm
- •At the inclusion, the ulcer will be clinically non-infected (according to IDSA criteria).
- •HbA1C < 12% at screening.
- •Absence of significant arterial insufficiency assessed by systolic homolateral ankle-brachial index (ABI) greater than 0.75 and inferior to 1.40 or biphasic or triphasic Doppler signals in the dorsalis or posterior tibial arteries of the affected limb.
排除标准
- •Subject has a history of:
- •endstage renal disease
- •uncontrolled cardiac failure
- •severe malnutrition
- •severe liver disease
- •aplastic anemia
- •malignant disease (active or recent (<5 years))diabetes avec HbA1C > 12%
- •rheumatoid arthritis
- •sickle cell disease
- •other connective tissue disorder
- •irradiation to the affected extremity
- •Serum creatinine concentration greater than 180 umol/L and/or receipt of renal dialysis or an estimated glomerular filtration rate (based on cystatin C or serum creatinine) of less than 20 mL/min per 1·73 m²
- •Drug or alcohol abuse.
- •Limited physical capacity or total immobility.
- •Known pregnancy or nursing at the time of screening visit
- •Subject is currently receiving (i.e within 30 days prior to inclusion) or scheduled to receive a medication or treatment that, in the opinion of the investigator, will interfere with or affect the rate of wound healing.
- •Index ulcers probing to tendon, muscle, capsule and bone.
- •Local or systemic signs of ongoing infection.
- •Hypersensitivity to silicone or porcine gelatin.
- •Previous treatment with growth factors, stem cells, or an equivalent preparation within the 8 weeks before the baseline visit.
- •Involvement in another interventional clinical trial within the 4 weeks before the baseline visit.
- •Known or suspected absence of capacity to understand the study procedures or provide written informed consent (decided by the investigator).
- •Cross-sectional area of the index ulcer had increased by at least 20%.
- •(for VLU only)
- •History of poor compliance with compression therapy.
- •Presence of peripheral neuropathy of the lower limbs.
- •(for DFU only)
- •History of poor compliance with offloading therapy.
研究组 & 干预措施
TrophiPatch treatment
Experimental
one time application of TrophiPatch
干预措施: TrophiPatch: allogeneic adipose-derived stromal cell patch (Drug)
结局指标
主要结局
Composite safety outcome at week 12 from baseline
时间窗: Week 12
Composite outcome including any of the following events: deterioration of the ulcer, as measured by an increase of the ulcer size of \> than 20% at week 12 as compared to d0; and/or presence of spreading infection or systemic infections (criteria according to IWII); and/or presence of treatment-related irritative or allergic contact dermatitis (as per clinical diagnosis)
次要结局
- Number of patients developing donor-HLA antibodies(Week 12)
- Weekly evolution of the wound bed score till week 12(From enrolment to week 12)
- Change in quality of life(Day 0 and week 12)
- Weekly change in ulcer area till week 12(from enrolment to week 12)
- Number of completely healed and epithelised ulcers at week 12.(Week 12)
- Number of patients with localised infection (TILI score ≥ 5) not suspicious for irritative or allergic contact dermatitis(Week 12)
- Extent of pruritus, as determined by Numerical Rating Score (NRS).(Week 12)
- Number of patients with hyper-cicatrisation(Week 12)
- Number of patients with pathologic scar(Week 12)
- Evolution of the quality of blood perfusion of the wound(Week 2 and week 12)
- Reduction in pain during the study period(From enrolment to week 12)
- Assessment of patient-relevant benefits during wound therapy(Day 0 and week 12)
研究者
Nicolò Brembilla
Clinical study coordinator
University Hospital, Geneva
研究点 (1)
Loading locations...
相似试验
招募中
2 期
SUBCUTANEOUS INJECTIONS OF AUTOLOGOUS CULTURED ADIPOSE-DERIVED STROMA/ STEM CELLS TO HEAL REFRACTORY ISCHEMIC DIGITAL ULCERS IN PATIENTS WITH SCLERODERMASystemic sclerosis2023-508432-53-00Centre Hospitalier Universitaire De Toulouse32
招募中
1 期
Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple SclerosisMultiple SclerosisNCT06592703Rennes University Hospital10
已完成
1 期
ADSC Injections for Pain Management of Osteoarthritis in the Human Knee JointOsteoarthritis of the KneeNCT02357485Fodor, Peter B, M.D.6
已完成
1 期
Clinical Trial Study About Human Adipose-Derived Stem Cells in the StrokeStrokeNCT02813512Gwo Xi Stem Cell Applied Technology Co., Ltd.3
终止
4 期
Lipogems Prospective StudyKnee OsteoarthritisNCT03922490Hospital for Special Surgery, New York2